Phase I study of sorafenib and tipifarnib for recurrent glioblastoma: NABTC 05-02

Recurrent glioblastoma (GBM) has a very low six-month progression free survival (PFS) with currently available treatments. Combination chemotherapy to target multiple cell signaling pathways is currently being investigated in order to improve prognosis for recurrent disease. The purpose of this phas...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Neurooncol
Main Authors: Nghiemphu, Phioanh Leia, Ebiana, Victoria Asuquo, Wen, Patrick, Gilbert, Mark, Abrey, Lauren E, Lieberman, F, DeAngelis, Lisa M, Robins, H Ian, Yung, WK Alfred, Chang, Susan, Drappatz, Jan, Mehta, Minesh P, Levin, Victor A, Aldape, Kenneth, Dancey, Janet E, Wright, JJ, Prados, Michael, Kuhn, John, Cloughesy, Timothy F.
Formato: Artigo
Idioma:Inglês
Publicado em: 2017
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5756101/
https://ncbi.nlm.nih.gov/pubmed/28988377
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11060-017-2624-4
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados